Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
2003 2
2004 8
2005 4
2006 5
2007 9
2008 7
2011 1
2012 2
2013 2
2014 2
2015 2
2016 2
2017 6
2018 4
2019 8
2020 8
2021 10
2022 14
2023 8
2024 8
2025 13
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

114 results

Results by year

Filters applied: . Clear all
Page 1
PT-141 Palatin.
Hedlund P. Hedlund P. Curr Opin Investig Drugs. 2004 Apr;5(4):456-62. Curr Opin Investig Drugs. 2004. PMID: 15134289 Review.
Palatin, under license from Competitive Technology, is developing the peptide PT-141, a synthetically modified analog of PT-14, as a nasal spray for the potential treatment of erectile dysfunction (ED) and female sexual dysfunction. ...
Palatin, under license from Competitive Technology, is developing the peptide PT-141, a synthetically modified analog of PT-14 …
Medical Treatment of Female Sexual Dysfunction.
Nappi RE, Tiranini L, Martini E, Bosoni D, Righi A, Cucinella L. Nappi RE, et al. Urol Clin North Am. 2022 May;49(2):299-307. doi: 10.1016/j.ucl.2022.02.001. Urol Clin North Am. 2022. PMID: 35428435 Review.
The therapeutic algorithm comprises a multidisciplinary approach, including pharmacologic and nonpharmacologic management. Flibanserin and bremelanotide are psychoactive agents indicated for the treatment of generalized acquired hypoactive sexual desire disorder (HSDD) in …
The therapeutic algorithm comprises a multidisciplinary approach, including pharmacologic and nonpharmacologic management. Flibanserin and …
Bremelanotide.
[No authors listed] [No authors listed] 2021 Aug 20. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2021 Aug 20. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 34436837 Free Books & Documents. Review.
Bremelanotide is a parenterally administered melanocortin receptor agonist that is used to treat female hypoactive sexual desire disorder. Bremelanotide has been reported to cause mild serum enzyme elevations during therapy and has been implicated in rare instances …
Bremelanotide is a parenterally administered melanocortin receptor agonist that is used to treat female hypoactive sexual desire diso …
Bremelanotide.
[No authors listed] [No authors listed] 2025 Feb 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2025 Feb 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 31369224 Free Books & Documents. Review.
No information is available on the clinical use of bremelanotide during breastfeeding. Because bremelanotide is a cyclic peptide molecule with a molecular weight of 1025, the amount in milk is likely to be very low and absorption is unlikely because it is probably d …
No information is available on the clinical use of bremelanotide during breastfeeding. Because bremelanotide is a cyclic pepti …
Hypoactive Sexual Desire Disorder in Women: Physiology, Assessment, Diagnosis, and Treatment.
Pettigrew JA, Novick AM. Pettigrew JA, et al. J Midwifery Womens Health. 2021 Nov;66(6):740-748. doi: 10.1111/jmwh.13283. Epub 2021 Sep 12. J Midwifery Womens Health. 2021. PMID: 34510696 Free PMC article. Review.
The 2 recently approved medications for HSDD, flibanserin and bremelanotide, are reviewed as well as off-label treatments. Overall, HSDD represents a common yet likely underrecognized disorder that midwives and other health care providers who care for women across the life …
The 2 recently approved medications for HSDD, flibanserin and bremelanotide, are reviewed as well as off-label treatments. Overall, H …
PT-141: a melanocortin agonist for the treatment of sexual dysfunction.
Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY. Molinoff PB, et al. Ann N Y Acad Sci. 2003 Jun;994:96-102. doi: 10.1111/j.1749-6632.2003.tb03167.x. Ann N Y Acad Sci. 2003. PMID: 12851303 Clinical Trial.
Administration of PT-141 to rats and nonhuman primates results in penile erections. Systemic administration of PT-141 to rats activates neurons in the hypothalamus as shown by an increase in c-Fos immunoreactivity. ...The results suggest that PT …
Administration of PT-141 to rats and nonhuman primates results in penile erections. Systemic administration of PT-14 …
Bremelanotide: First Approval.
Dhillon S, Keam SJ. Dhillon S, et al. Drugs. 2019 Sep;79(14):1599-1606. doi: 10.1007/s40265-019-01187-w. Drugs. 2019. PMID: 31429064 Review.
Bremelanotide (Vyleesi ) is a melanocortin receptor agonist recently approved in the USA for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), as characterized by low sexual desire that causes marked distress or inter …
Bremelanotide (Vyleesi ) is a melanocortin receptor agonist recently approved in the USA for the treatment of premenopausal women wit …
Targeting the central melanocortin system for the treatment of metabolic disorders.
Sweeney P, Gimenez LE, Hernandez CC, Cone RD. Sweeney P, et al. Nat Rev Endocrinol. 2023 Sep;19(9):507-519. doi: 10.1038/s41574-023-00855-y. Epub 2023 Jun 26. Nat Rev Endocrinol. 2023. PMID: 37365323 Review.
Furthermore, the FDA approvals in 2019 of two peptide drugs targeting melanocortin receptors for the treatment of generalized hypoactive sexual desire disorder (bremelanotide) and erythropoietic protoporphyria-associated phototoxicity (afamelanotide) demonstrate the safety …
Furthermore, the FDA approvals in 2019 of two peptide drugs targeting melanocortin receptors for the treatment of generalized hypoactive sex …
Pharmacologic therapeutic options for sexual dysfunction.
Burton CS, Mishra K. Burton CS, et al. Curr Opin Obstet Gynecol. 2022 Dec 1;34(6):402-408. doi: 10.1097/GCO.0000000000000821. Curr Opin Obstet Gynecol. 2022. PMID: 36036468 Review.
SUMMARY: Pharmacologic treatment with local estrogen and testosterone replacement in postmenopausal individuals and with centrally-acting therapies such as flibanserin, bremelanotide, and testosterone in premenopausal individuals assigned female at birth are safe and can b …
SUMMARY: Pharmacologic treatment with local estrogen and testosterone replacement in postmenopausal individuals and with centrally-acting th …
Pharmacotherapy for Sexual Dysfunction in Women.
Lee JH, Lee JE, Harsh V, Clayton AH. Lee JH, et al. Curr Psychiatry Rep. 2022 Feb;24(2):99-109. doi: 10.1007/s11920-022-01322-7. Epub 2022 Feb 1. Curr Psychiatry Rep. 2022. PMID: 35102537 Review.
RECENT FINDINGS: Include delineation of the process of care for pre- and postmenopausal women with HSDD; release of global position statement on testosterone therapy in women; updates on efficacy and safety of vaginal estrogen for genitourinary syndrome of menopause and bremel …
RECENT FINDINGS: Include delineation of the process of care for pre- and postmenopausal women with HSDD; release of global position statemen …
114 results